Eli Lilly’s Pain Is A Success For These Companies

The mothballing of Eli Lilly’s (NYSE:LLY) once-promising next-generation cholesterol drug, evacetrapib, eliminates a potential competitor to Regeneron (NASDAQ:REGN) and Amgen’s (NASDAQ:AMGN) recently launched cholesterol busters while also reducing pressure on Esperion Therapeutics (NASDAQ:ESPR) to get its promising new anti-cholesterol drug to market sooner. Because Eli Lilly’s decision may have significantly shifted how the cholesterol treatment market may look in the coming years, let’s take a closer look.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC